Literature DB >> 28580595

Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients.

Y Xie1,2, G Li1, M Chen3, X Guo3, L Tang4, X Luo3, S Wang4, W Yi5, L Dai3,6,7, J Wang1.   

Abstract

Variants of cancer susceptibility genes other than BRCA1/2 have been proved to be associated with increased risks of breast cancer. This study was performed to investigate the spectrum and prevalence of mutations in 10 cancer susceptibility genes in paired tumor/normal tissues of 292 unselected Chinese breast cancer patients. We performed an analysis of germline and somatic variants in ATM, CDH1, CHEK2, ESR1, GATA3, MAP3K1, MSH2, PALB2, RB1 and STK11 genes by integrating microfluidic PCR-based target enrichment and next-generation sequencing technologies. In total, 3 germline and 25 somatic deleterious mutations were found among 27 patients (9.25%), and 17 of them were novel mutations. Most deleterious mutations were prevalent in luminal A invasive breast cancer (P = .014). We also observed 83 variants of uncertain significance (VUS) in 100 patients (34.25%), 23 of which were predicted to be deleterious by in silico prediction programs (MetaSVM and MetaLR). VUS carriers had higher positive rate of lymph node metastasis than non-carriers (P = .008) and were predominantly present in ER+ tumors (P = .018). Our findings would enhance the understanding of the molecular mechanisms of breast cancer in Chinese population.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  breast cancer; cancer susceptibility gene; microfluidic PCR; mutation; next-generation sequencing

Mesh:

Year:  2017        PMID: 28580595     DOI: 10.1111/cge.13063

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  4 in total

1.  Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.

Authors:  Guoli Li; Xinwu Guo; Ming Chen; Lili Tang; Hui Jiang; Julia X Day; Yueliang Xie; Limin Peng; Xunxun Xu; Jinliang Li; Shouman Wang; Zhi Xiao; Lizhong Dai; Jun Wang
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

2.  Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.

Authors:  Elizabeth Elliott; Virginia Speare; James Coggan; Carin Espenschied; Holly LaDuca; Amal F Yussuf; Kelly Burgess; Phillip Gray; Melody Cobleigh; Ruta Rao; Jeremy Patel; Timothy Kuzel; Lela E Buckingham; Lydia Usha
Journal:  Cancer Rep (Hoboken)       Date:  2020-09-03

Review 3.  PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.

Authors:  Laetitia Collet; Julien Péron; Frédérique Penault-Llorca; Pascal Pujol; Jonathan Lopez; Gilles Freyer; Benoît You
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

Review 4.  Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability.

Authors:  Sarah A Jeffreys; Branka Powter; Bavanthi Balakrishnar; Kelly Mok; Patsy Soon; André Franken; Hans Neubauer; Paul de Souza; Therese M Becker
Journal:  Cells       Date:  2020-09-11       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.